Organisation paid for research Program year 2025 Source: CMS Open Payments

Center for Clinical Studies Ltd LLP

Neither a doctor nor a teaching hospital

Research payments

$10,938,356

2,244 payments

Through program year 2025, Center for Clinical Studies Ltd LLP is reported as receiving $10,938,356 in research payments, across 2,244 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,244,919	321
2024	Research	$1,426,325	485
2023	Research	$772,123	337
2022	Research	$906,312	180
2021	Research	$1,567,238	309
2020	Research	$2,002,955	317
2019	Research	$3,018,483	295

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $4,145,721 832 payments
Eli Lilly and Company $1,844,342 107 payments
Pfizer Inc. $1,723,100 270 payments
Janssen Research & Development, LLC $1,164,178 265 payments
Sanofi US Services Inc. $337,635 67 payments
LEO Pharma AS $333,601 55 payments
Kyowa Kirin Pharmaceutical Development, Inc $329,363 17 payments
Sun Pharmaceutical Industries Inc. $314,088 122 payments
Aclaris Therapeutics, Inc. $137,051 16 payments
Dermavant Sciences, Inc. $115,835 300 payments

Studies the money was for Research payments · program years 2019–2025

M15-997 $921,549 134 payments
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $600,705 6 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata $473,953 21 payments
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) $402,037 82 payments
M16-766 $369,894 39 payments
Phase 2AB Safety and Efficacy Study of Pf06700841 in Patients With Moderate Psoriasis $356,159 41 payments
Phase 2AB Safety and Efficacy Study of Pf06700841 in Atopic Dermatitis Patients $307,108 24 payments
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $297,791 78 payments
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis $291,919 73 payments
M16-047 $239,656 62 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.